AAV Vector miR-183 Targeting for DRG Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy using adeno-associated viruses (AAV) faces toxicity issues, particularly in the CNS and musculoskeletal system, leading to severe side effects such as neuronal degeneration in dorsal root ganglia, which limits the clinical impact of this technology.
Innovation Solution
A recombinant AAV vector is developed with a coding sequence for a gene product under the control of regulatory sequences, combined with at least eight microRNA (miR) target sequences specific for miR-183 or miR-182, which are operably linked to the 3' end of the coding sequence to repress gene product expression in dorsal root ganglia, thereby minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high doses of AAV vectors are administered to target the CNS and musculoskeletal system, then transduction efficiency is improved, but severe toxicities including neuronal degeneration in dorsal root ganglia occur
Solution Approach 1:
The patent applies local quality by making the transgene expression tissue-specific through the use of miR-183 target sequences. These sequences are specifically expressed in dorsal root ganglia, allowing the transgene to be repressed only in this sensitive tissue while maintaining expression in other target tissues such as muscle and CNS. This resolves the contradiction by enabling high-dose administration for improved transduction efficiency while preventing localized toxicity in the dorsal root ganglia.
Solution Approach 2:
The patent uses miR-183 target sequences as an intermediary mechanism to control transgene expression. These sequences act as mediators that are naturally present in dorsal root ganglia but absent or low in other tissues. By incorporating these sequences into the transgene construct, the patent creates a regulatory mechanism that automatically suppresses expression in sensitive tissues without requiring external intervention, thus enabling safe high-dose administration.
2Reliability
If AAV vectors are used for gene therapy delivery, then safety profile is improved compared to non-viral and adenoviral vectors, but acute toxicities including thrombocytopenia and transaminitis occur at high doses
Solution Approach 1:
The patent applies parameter changes by modifying the transgene expression regulation through the incorporation of miR-183 target sequences. This changes the expression parameter from constitutive to tissue-specific, thereby reducing overall transgene load in sensitive tissues. This allows high-dose vector administration to maintain improved safety profile while reducing the incidence of acute toxicities such as thrombocytopenia and transaminitis that occur with conventional high-dose AAV therapy.
3Productivity
If constitutive expression of transgene is used, then therapeutic efficacy is maximized, but toxicity in sensitive cell types cannot be avoided
Solution Approach 1:
The patent transforms constitutive expression into local quality expression by incorporating miR-183 target sequences. These sequences are naturally expressed only in dorsal root ganglia, creating a local regulatory effect that suppresses transgene expression specifically in this sensitive tissue. This allows the transgene to maintain high expression levels in therapeutic tissues (muscle, CNS) for maximized efficacy while automatically avoiding expression in sensitive cell types, thus resolving the contradiction between therapeutic efficacy and toxicity prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces transgene expression in dorsal root ganglia, decreasing neuronal degeneration and secondary axonal degeneration, while allowing enhanced expression in other cell types, thereby minimizing toxicity and maintaining therapeutic efficacy.
Implementation Method 1
at least eight miR target sequences, wherein each target sequence is specific for miR-183 or miR-182, and wherein the at least eight miR target sequences are operably linked to the 3' end of the coding sequence
Data Source
AI summary
A recombinant AAV (rAAV) for delivery of a gene product to a patient in need thereof which specifically represses expression of the gene product in dorsal root ganglia (DRG) is provided. The rAAV comprises an AAV capsid having packaged therein a vector genome, wherein the vector genome comprises: (a) a coding sequence for the gene product under the control of regulatory sequences that direct expression of the gene product in a cell containing the vector genome; and (b) at least eight miR target sequences, wherein each target sequence is specific for miR-183 or miR-182, and wherein the at least eight miR target sequences are operably linked to the 3′ end of the coding sequence. Also provided are methods and uses of the described rAAVs for delivery of a gene product to a patient in need thereof.